What is the Projected CAGR value of the Tardive Dyskinesia Treatment Market ?
Tardive Dyskinesia Treatment Market is expected to grow at a CAGR of 4% during the forecast period 2023-2030.
Who are the key players in Tardive Dyskinesia Treatment Market ?
Major players are Neurocrine Biosciences, Inc., Teva Pharmaceutical Industries Ltd, Pfizer Inc., Biogen, Novartis AG, Johnson & Johnson Services, Inc., AstraZeneca, GlaxoSmithKline plc., Bayer AG, Sanofi, Shanghai Pharmaceutical Group Co., Ltd., China Resources Pharmaceutical GroupCo., Ltd. and Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd.